(Reuters) – Drugmaker AstraZeneca said on Tuesday its cancer drug Imfinzi administered with chemoradiotherapy failed to meet its main goal in a late-stage trial to treat unresectable, Stage 3 non-small cell lung cancer.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Rashmi Aich)
